Mode
Text Size
Log in / Sign up

Meta-analysis shows intraovarian PRP improves ovarian markers but pregnancy rates remain unchanged in women with poor reservePlatelet-rich plasma improves ovarian markers but not pregnancy rates yet

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Intraovarian PRP improves ovarian markers but does not significantly improve pregnancy rates in women with poor reserve.

This meta-analysis evaluated intraovarian autologous platelet-rich plasma (PRP) in women facing poor ovarian reserve or ovarian insufficiency. The study pooled data from 422 participants to assess the impact of this intervention on key reproductive metrics compared to control groups.

Results indicated significant improvements in several ovarian function markers. Antral follicle count increased with a mean difference of 0.81, while anti-Müllerian hormone levels rose substantially. Conversely, follicle-stimulating hormone levels decreased, and estradiol concentrations increased, all pointing toward enhanced ovarian activity.

Despite these favorable hormonal shifts, the analysis found no significant improvement in pregnancy rates. The authors caution that current evidence remains insufficient to define the optimal PRP regimen or identify the patient subgroups most likely to benefit from this approach.

Limitations included a limited number of studies and heterogeneity in treatment protocols. Consequently, findings should be interpreted cautiously until further research clarifies the clinical utility of intraovarian PRP for improving live birth outcomes.

Imagine waking up and feeling hopeful about your future family. You have been told your ovaries are not working as well as they should. Doctors call this poor ovarian reserve. You might feel like there is no good option left for you.

But new research offers a different view. Scientists are looking at a treatment called intraovarian autologous platelet-rich plasma. This sounds complicated, but the idea is simple. It uses your own blood to help your ovaries heal.

Many women struggle with diminished ovarian reserve. This condition means your ovaries have fewer eggs than expected. It can happen at any age. It is frustrating because current treatments often fail to restore egg numbers.

Doctors usually suggest waiting or using donor eggs. These options are expensive and emotionally hard. Patients need better choices that work with their own biology.

The Old Way Vs New Way

For years, doctors focused on hormones to trick the body into making more eggs. This approach often had mixed results. It did not fix the underlying problem in the ovaries.

But here is the twist. This new research looks at putting platelet-rich plasma directly into the ovaries. Platelets are cells that help healing. They carry proteins that repair tissue. This method targets the problem inside the organ.

A Factory That Needs Repair

Think of your ovaries as a factory. This factory makes eggs. Sometimes the machines break down. The factory slows production. Platelet-rich plasma acts like a repair crew. It brings tools to fix the broken machines.

The repair crew releases signals that tell the factory to work better. It helps the factory produce more eggs. It also improves the quality of the eggs being made.

This review looked at seven studies with 422 women. The women had poor ovarian reserve or ovarian insufficiency. They received the platelet-rich plasma treatment or a placebo.

The results were clear on some measures. The number of small eggs on the ovary surface went up. This is called the antral follicle count. The hormone that shows egg supply also went up.

Another hormone that drops when egg supply is low also went down. This is a good sign. It means the ovaries are responding better.

This doesn't mean this treatment is available yet.

However, the most important result was missing. The treatment did not significantly increase pregnancy rates. Women did not get pregnant more often than those who did not get the treatment.

This news is mixed. The treatment improves the signs of ovarian health. But it does not yet prove it helps you get pregnant. You should talk to your doctor before trying this.

It is important to know that this is still early stage. The treatment is not approved for routine use. It might be available in research clinics. Your doctor can tell you if you qualify.

The study has some limits. There were only seven studies. The number of women was small. The treatment methods varied between studies. This makes it hard to know exactly how to use it best.

More research is needed to find the right dose. Doctors also need to know which patients benefit most. We need to understand who gets the best results.

Scientists will continue to study this treatment. They will look for better ways to use it. The goal is to help more women build families.

It may take years to get full approval. Research takes time to prove safety and effectiveness. Stay hopeful but patient. New options are coming for women with low egg supply.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
BackgroundPoor ovarian reserve and ovarian insufficiency pose major challenges in reproductive medicine, with limited effective therapeutic options. Intraovarian autologous platelet-rich plasma (PRP) has shown potential benefits, but its efficacy remains uncertain based on current randomized controlled trials (RCTs).MethodsThis review followed PRISMA guidelines and was registered in PROSPERO (CRD420251233432). We systematically searched PubMed, Cochrane Central, Embase, CNKI, VIP, and Wanfang up to November 22, 2025, for randomized controlled trials of intraovarian autologous PRP in women with diminished ovarian reserve or ovarian insufficiency. Meta-analyses were performed using Stata 16, with heterogeneity assessed by the I² statistic. Risk of bias and study quality were evaluated using the Cochrane RoB 2 tool and the PEDro scale. Primary outcomes included serum anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), antral follicle count (AFC), and pregnancy rates.Result(s)This meta-analysis included seven RCTs involving 422 women with poor ovarian reserve or ovarian insufficiency/failure. PRP treatment was associated with significant improvements in several ovarian reserve-related parameters: AFC increased (MD = 0.81, 95% CI 0.31 to 1.30; I² = 41.63%), AMH increased (SMD = 0.91, 95% CI 0.41 to 1.42; I² = 54.32%), FSH decreased (MD = -5.72, 95% CI -7.03 to -4.41; I² = 0.00%), and estradiol increased (MD = 26.03, 95% CI 19.53 to 32.53; I² = 0.22%). However, PRP treatment did not significantly improve pregnancy rates compared with controls.ConclusionsThis meta-analysis suggests that intraovarian PRP may improve ovarian reserve-related markers in women with poor ovarian reserve or ovarian insufficiency/failure, but it does not appear to increase pregnancy rates significantly. These findings should be interpreted cautiously because of the limited number of studies and heterogeneity in treatment protocols, and current evidence remains insufficient to define the optimal PRP regimen or the patient subgroups most likely to benefit.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420251233432, identifier CRD420251233432.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.